Longevity
-
What actually moves an epigenetic clock, and what does not
The interventions the longevity market sells hardest are the ones with no detectable effect on the clocks it sells alongside them. Two reviews in 2026 make that awkwardly clear.
-
Does lowering blood pressure prevent dementia? What the trials actually show
Hypertension sits at the top of every modifiable dementia risk list, almost entirely on observational data. The randomized question is harder, and it has only recently been answered.
-
Do statins buy healthspan? What STAREE found in 10,000 healthy adults over 70
The first big trial to ask whether a primary prevention statin buys good years rather than just fewer events. It got a clean answer, and the answer was no.
-
The rapamycin reversal: why the longevity crowd is backing off
The best-evidenced longevity drug in mice had its confidence knocked in 2024 and 2025. A null human trial, a null on the epigenetic clocks, and one very public quit.
-
What epigenetic clocks actually measure (DunedinPACE vs GrimAge vs PhenoAge)
Three popular clocks give three different answers because they were trained on three different things. One measures mortality risk, one measures your rate of aging, and a single reading is noisier than the marketing admits.